Results 21 to 30 of about 152,710 (293)

Intravenous immunoglobulin is safe and effective in controlling pre-existing paraneoplastic neuromuscular diseases in cancer patients treated with immune checkpoint inhibitors: two case reports and literature review

Frontiers in Oncology, 2023
Immune checkpoint inhibitors cause rare but potentially fatal neuromuscular complications, leading to a concern to use these agents in cancer patients with pre-existing autoimmune or inflammatory neuromuscular diseases.
Ge Xiong, Richard Benjamin Young, Helen Chow, Emanual Maverakis, Ricardo A. Maselli, David Paul Richman, Tianhong Li   +6 more
doaj   +1 more source

Bell's palsy during rechallenge of immune checkpoint inhibitor

IJU Case Reports, 2023
Introduction The peripheral nervous system is one of the target organs of immune‐related adverse events. Peripheral facial nerve palsy, also called Bell's palsy, which is induced by immune checkpoint inhibitors, is quite rare, and its clinical features ...
Kohji Takemura, Taro Yamanaka, Michikata Hayashida, Rika Kizawa, Takeshi Yamaguchi, Yuko Tanabe, Kazushige Sakaguchi, Koichi Suyama, Shinji Urakami, Yuji Miura   +9 more
doaj   +1 more source

Immune checkpoint inhibitor myocarditis: a systematic case study

Российский кардиологический журнал, 2020
Myocarditis is a life-threatening complication of immune checkpoint inhibitor therapy. Over the past ten years, drugs in this group have been used in the treatment of a wide range of hematological diseases and solid tumors.
E. A. Kushnareva, O. M. Moiseeva
doaj   +1 more source

Immune Checkpoint Inhibitor-Associated Myocarditis

JACC: Case Reports, 2020
Immune checkpoint inhibitors (ICIs) can induce immunity-related adverse events. We demonstrate the clinical use of cardiac magnetic resonance and endomyocardial biopsy in the diagnosis and subsequent monitoring of ICI-associated myocarditis, suggesting ...
Grigorios Chatzantonis, MD, Georg Evers, MD, Claudia Meier, MD, Michael Bietenbeck, PhD, Anca Florian, MD, Karin Klingel, MD, Annalen Bleckmann, MD, Ali Yilmaz, MD   +7 more
doaj   +1 more source

Nano-Chemotherapy synergize with immune checkpoint inhibitor- A better option?

Frontiers in Immunology, 2022
Immune checkpoint inhibitor (ICI) is one of the most important tumor treatment methods. Although the therapeutic efficiency of immune checkpoint inhibitor mono-therapy is limited, the combination of chemotherapy plus immune checkpoint inhibitors has ...
Xinye Qian, Xinye Qian, Wang Hu, Wang Hu, Jun Yan, Jun Yan   +5 more
doaj   +1 more source

Immune checkpoint inhibitor-associated sarcoidosis reaction [PDF]

Journal of Nephropathology, 2023
Immune checkpoint inhibitors (ICIs) constitute a class of drugs that stimulate the immune system to fight cancer cells. However, they can also induce immune-related adverse events (irAEs) in various organs, including the kidneys.
Parisa Keshtgar, Parisa Kaviani, Payam Peymani, Neda Kianpour, Samin Karamian   +4 more
doaj   +1 more source

Efficacy and Safety of Immune Checkpoint Inhibitors Therapy on Advanced Gastric Cancer or Gastroesophageal Junction Cancer: A Meta-analysis

Zhongliu Fangzhi Yanjiu, 2021
Objective To systematically evaluate the efficacy and safety of immune checkpoint inhibitors in the treatment of advanced gastric cancer or gastroesophageal junction cancer (GC/GEJC).
SHAN Yujie, LIANG Ping, LYU Yalei, WANG Long, ZHANG Xiaolin, SHAN Baoen   +5 more
doaj   +1 more source

Immune Checkpoint Inhibitor Therapy Associated Hypophysitis

Clinical Medicine Insights: Endocrinology and Diabetes, 2015
Ipilimumab is a monoclonal antibody directed against CTLA4 T-lymphocyte antigen used as cancer therapy. Immune-related adverse events are common side effects and may include hypophysitis-related hypopituitarism. The clinical features of six patients with
Moeber Mahzari, Dora Liu, Amel Arnaout, Heather Lochnan   +3 more
doaj   +2 more sources

Nivolumab induced remitting seronegative symmetrical synovitis with pitting edema in a patient with melanoma: a case report

Journal of Medical Case Reports, 2018
Background Novel immune checkpoint inhibitors have been often utilized for different types of malignancies as salvage therapy with varying success. One obstacle to immune checkpoint inhibitor use is the higher incidence of immune-mediated side effects ...
Linh Ngo, Eric Miller, Peter Valen, Elie Gertner   +3 more
doaj   +1 more source

Avelumab-Induced Scleroderma in a Patient with Metastatic Squamous Cell Carcinoma of the Lung

Case Reports in Dermatological Medicine, 2022
Immune checkpoint inhibitors are associated with a spectrum of cutaneous immune-related adverse events. While maculopapular eruptions are the most common cutaneous adverse event, scleroderma can rarely develop.
Jeffrey L. Dobrzynski, Blake E. Vest, Brian L. Swick   +2 more
doaj   +1 more source